Download PDF
Zeitschrift für Orthomolekulare Medizin 2013; 11(4): 9-14
DOI: 10.1055/s-0033-1360147
Wissen
Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart · New York

Vitamin C in der komplementären Onkologie: Update 2013

Uwe Gröber
Further Information

Publication History

Publication Date:
18 December 2013 (online)

    Permissions and Reprints

Zusammenfassung

Vitamin C wird seit Langem in der komplementären Onkologie eingesetzt. In- vitro-Studien und Tierversuche zeigen eine zytotoxische Wirkung des Vitamins auf Tumorzellen. Kleinere Studien und internationale Fallberichte deuten darauf hin, dass Krebspatienten von einer Vitamin-C-Hochdosisinfusionstherapie im Hinblick auf die Nebenwirkungen und Effektivität einer tumordestruktiven Therapie profitieren können.

Schlüsselwörter

Vitamin C - komplementäre Onkologie - Pharmakokinetik - zytotoxische Effekte - Wasserstoffperoxid - Zytostatika - Nebenwirkungsrate

Literaturverzeichnis als PDF

 

  • Literatur

  • 1 Golde DW. Vitamin C in cancer. Integr Cancer Ther 2003; 2 (2) 158-159
    CrossrefGoogle Scholar
  • 2 Gröber U, Mücke R, Holzhauer P, Kisters K. Micronutrients in oncology. Current data about vitamin D, selenium, L-carnitine and vitamin C. Med Monatsschr Pharm 2013; 36 (4) 133-143
    Google Scholar
  • 3 Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 1974; 9 (4) 285-315
    CrossrefGoogle Scholar
  • 4 Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1976; 73 (10) 3685-3689
    CrossrefGoogle Scholar
  • 5 Creagan ET et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301 (13) 687-690
    CrossrefGoogle Scholar
  • 6 Moertel CG et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985; 312 (3) 137-141
    CrossrefGoogle Scholar
  • 7 Pietrzik K, Golly I, Loew D. Handbuch: Vitamine. München: Elsevier Verlag; 2008
    Google Scholar
  • 8 Padayatty JS et al. Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med 2004; 140 (7) 533-538
    CrossrefGoogle Scholar
  • 9 Chen Q et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as prodrug to deliver hydrogen peroxide to tissues. PNAS 2005; 102 (38) 13604-13609
    CrossrefGoogle Scholar
  • 10 Chen Q et al. Pharmacologic doses of ascorbate act as prooxidant and decrease growth of aggressive tumor xenografts in mice. PNAS 2008; 105 (32) 11037-11038
    CrossrefGoogle Scholar
  • 11 Gröber U. Vitamin C in complementary oncology – Update 2009. Med Monatsschr Pharm 2009; 37 (7) 263-267
    Google Scholar
  • 12 Gröber U. Antioxidants and other micronutrients in complementary oncology. Breast Care 2009; 4 (1) 13-20
    CrossrefPubMedGoogle Scholar
  • 13 Vollbracht C, Schneider B, Leendert V et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and after care: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 2011; 25: 983-990
    Google Scholar
  • 14 Shimpo K et al. Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 1991; 54 (Suppl. 06) 1298S-1301S
    Google Scholar
  • 15 Kurbacher CM et al. Ascorbic acid improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 1996; 103 (2) 183-189
    CrossrefGoogle Scholar
  • 16 Prasad KN et al. Modification of the effect of tamoxifen, cisplatin, DTIC, and interferon-α2b on human melanoma cells in culture by mixture of vitamins. Nutr Cancer 1994; 22: 233-245
    CrossrefGoogle Scholar
  • 17 Taper HS et al. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. In J Cancer 1987; 40 (4) 575-579
    Google Scholar
  • 18 Calderon PB et al. Potential therapeutic application of the association of vitamins C and K3 in cancer treatment. Curr Med Chem 2002; 9 (24) 2271-2285
    CrossrefGoogle Scholar
  • 19 Gröber U, Mücke R et al. Komplementärer Einsatz von Antioxidanzien und Mikronährstoffen in der Onkologie – Update 2013. Der Onkologe 2013; 19 (2) 136-143
    CrossrefGoogle Scholar
  • 20 Drisko JA et al. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 2003; 22 (2) 118-123
    CrossrefGoogle Scholar
  • 21 Padayatty SJ et al. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006; 174 (7) 937-942
    CrossrefGoogle Scholar
  • 22 Gröber U. Vitamin-C-Hochdosisinfusionstherapie beim Mammakarzinom: Falldarstellung der Vitamin-C-Hochdosisinfusionstherapie GL. Deutsche Zeitschrift für Onkologie 2007; 39 (2) 80-81
    Article in Thieme ConnectGoogle Scholar
  • 23 Welsh JL, Wagner BA, Vanʼt Erve TJ et al. Pharmacological ascorbate with gemcitabine for the control of metastastic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 2013; 71 (3) 765-775
    CrossrefGoogle Scholar
  • 24 Gröber U, Holzhauer P, Kisters K. Besser durch die Krebstherapie: Mehr Lebensqualität mit den richtigen Vitaminen und anderen Mikronährstoffen. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2014
    CrossrefGoogle Scholar